Observational pilot study of switching from entecavir to tenofovir alafenamide in patients with chronic hepatitis B
Abstract This study evaluated the long-term efficacy and safety of the widely used drugs entecavir (ETV) and tenofovir alafenamide (TAF), as well as the incidence of HCC.A nonrandomized, prospective, observational analysis included 77 patients with chronic hepatitis B who were assigned to continue E...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-01-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-025-85317-3 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841544706172911616 |
|---|---|
| author | Takuya Matsubara Satoru Hagiwara Naoshi Nishida Naoya Omaru Akihiro Yoshida Tomoki Yamamoto Yoriaki Komeda Mamoru Takenaka Masatoshi Kudo |
| author_facet | Takuya Matsubara Satoru Hagiwara Naoshi Nishida Naoya Omaru Akihiro Yoshida Tomoki Yamamoto Yoriaki Komeda Mamoru Takenaka Masatoshi Kudo |
| author_sort | Takuya Matsubara |
| collection | DOAJ |
| description | Abstract This study evaluated the long-term efficacy and safety of the widely used drugs entecavir (ETV) and tenofovir alafenamide (TAF), as well as the incidence of HCC.A nonrandomized, prospective, observational analysis included 77 patients with chronic hepatitis B who were assigned to continue ETV or switch TAF. After 240 weeks, the mean changes in serum hepatitis B surface antigen (− 0.365 ± 0.069 log IU/mL vs. 0.301 ± 0.039 log IU/mL, p = 0.39) and hepatitis B core-related antigen (− 0.215 ± 0.092 log IU/mL vs. − 0.195 ± 0.056 log IU/mL) were not significantly different between the ETV and TAF groups. There were also no differences between the two groups in estimated glomerular filtration rate (− 5.407 ± 1.660 vs. − 2.666 ± 1.52, p = 0.240), urinary β2-microglobulin β/creatinine (ETV: 2.330 ± 0.374 at baseline and 2.335 ± 0.257 at 240 weeks; TAF: 2.720 ± 0.073 and 2.123 ± 0.310, p = 0.996 and 0.455, respectively) or urinary N-acetyl-β-D-glucosaminidase/creatinine (ETV: 0.040 ± 0.005 at baseline and 0.044 ± 0.004 at 240 weeks; TAF: 0.049 ± 0.005 and 0.053 ± 0.005, p = 0.642 and 0.684, respectively). Finally, no significant difference was found in the incidence of HCC between the ETV and TAF groups (log-rank test, p = 0.08). In conclusion, the long-term observation of this study demonstrated that ETV and TAF have comparable efficacy and safety. Clinical trial registration: UMIN000026465. |
| format | Article |
| id | doaj-art-e4baba08570b42b8bc90b62e078bf0bf |
| institution | Kabale University |
| issn | 2045-2322 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj-art-e4baba08570b42b8bc90b62e078bf0bf2025-01-12T12:20:54ZengNature PortfolioScientific Reports2045-23222025-01-0115111210.1038/s41598-025-85317-3Observational pilot study of switching from entecavir to tenofovir alafenamide in patients with chronic hepatitis BTakuya Matsubara0Satoru Hagiwara1Naoshi Nishida2Naoya Omaru3Akihiro Yoshida4Tomoki Yamamoto5Yoriaki Komeda6Mamoru Takenaka7Masatoshi Kudo8Department of Gastroenterology and Hepatology, Kindai University Faculty of MedicineDepartment of Gastroenterology and Hepatology, Kindai University Faculty of MedicineDepartment of Gastroenterology and Hepatology, Kindai University Faculty of MedicineDepartment of Gastroenterology and Hepatology, Kindai University Faculty of MedicineDepartment of Gastroenterology and Hepatology, Kindai University Faculty of MedicineDepartment of Gastroenterology and Hepatology, Kindai University Faculty of MedicineDepartment of Gastroenterology and Hepatology, Kindai University Faculty of MedicineDepartment of Gastroenterology and Hepatology, Kindai University Faculty of MedicineDepartment of Gastroenterology and Hepatology, Kindai University Faculty of MedicineAbstract This study evaluated the long-term efficacy and safety of the widely used drugs entecavir (ETV) and tenofovir alafenamide (TAF), as well as the incidence of HCC.A nonrandomized, prospective, observational analysis included 77 patients with chronic hepatitis B who were assigned to continue ETV or switch TAF. After 240 weeks, the mean changes in serum hepatitis B surface antigen (− 0.365 ± 0.069 log IU/mL vs. 0.301 ± 0.039 log IU/mL, p = 0.39) and hepatitis B core-related antigen (− 0.215 ± 0.092 log IU/mL vs. − 0.195 ± 0.056 log IU/mL) were not significantly different between the ETV and TAF groups. There were also no differences between the two groups in estimated glomerular filtration rate (− 5.407 ± 1.660 vs. − 2.666 ± 1.52, p = 0.240), urinary β2-microglobulin β/creatinine (ETV: 2.330 ± 0.374 at baseline and 2.335 ± 0.257 at 240 weeks; TAF: 2.720 ± 0.073 and 2.123 ± 0.310, p = 0.996 and 0.455, respectively) or urinary N-acetyl-β-D-glucosaminidase/creatinine (ETV: 0.040 ± 0.005 at baseline and 0.044 ± 0.004 at 240 weeks; TAF: 0.049 ± 0.005 and 0.053 ± 0.005, p = 0.642 and 0.684, respectively). Finally, no significant difference was found in the incidence of HCC between the ETV and TAF groups (log-rank test, p = 0.08). In conclusion, the long-term observation of this study demonstrated that ETV and TAF have comparable efficacy and safety. Clinical trial registration: UMIN000026465.https://doi.org/10.1038/s41598-025-85317-3CarcinogenesisEfficacyEntecavirHepatitis B virusSafetyTenofovir alafenamide |
| spellingShingle | Takuya Matsubara Satoru Hagiwara Naoshi Nishida Naoya Omaru Akihiro Yoshida Tomoki Yamamoto Yoriaki Komeda Mamoru Takenaka Masatoshi Kudo Observational pilot study of switching from entecavir to tenofovir alafenamide in patients with chronic hepatitis B Scientific Reports Carcinogenesis Efficacy Entecavir Hepatitis B virus Safety Tenofovir alafenamide |
| title | Observational pilot study of switching from entecavir to tenofovir alafenamide in patients with chronic hepatitis B |
| title_full | Observational pilot study of switching from entecavir to tenofovir alafenamide in patients with chronic hepatitis B |
| title_fullStr | Observational pilot study of switching from entecavir to tenofovir alafenamide in patients with chronic hepatitis B |
| title_full_unstemmed | Observational pilot study of switching from entecavir to tenofovir alafenamide in patients with chronic hepatitis B |
| title_short | Observational pilot study of switching from entecavir to tenofovir alafenamide in patients with chronic hepatitis B |
| title_sort | observational pilot study of switching from entecavir to tenofovir alafenamide in patients with chronic hepatitis b |
| topic | Carcinogenesis Efficacy Entecavir Hepatitis B virus Safety Tenofovir alafenamide |
| url | https://doi.org/10.1038/s41598-025-85317-3 |
| work_keys_str_mv | AT takuyamatsubara observationalpilotstudyofswitchingfromentecavirtotenofoviralafenamideinpatientswithchronichepatitisb AT satoruhagiwara observationalpilotstudyofswitchingfromentecavirtotenofoviralafenamideinpatientswithchronichepatitisb AT naoshinishida observationalpilotstudyofswitchingfromentecavirtotenofoviralafenamideinpatientswithchronichepatitisb AT naoyaomaru observationalpilotstudyofswitchingfromentecavirtotenofoviralafenamideinpatientswithchronichepatitisb AT akihiroyoshida observationalpilotstudyofswitchingfromentecavirtotenofoviralafenamideinpatientswithchronichepatitisb AT tomokiyamamoto observationalpilotstudyofswitchingfromentecavirtotenofoviralafenamideinpatientswithchronichepatitisb AT yoriakikomeda observationalpilotstudyofswitchingfromentecavirtotenofoviralafenamideinpatientswithchronichepatitisb AT mamorutakenaka observationalpilotstudyofswitchingfromentecavirtotenofoviralafenamideinpatientswithchronichepatitisb AT masatoshikudo observationalpilotstudyofswitchingfromentecavirtotenofoviralafenamideinpatientswithchronichepatitisb |